In summary, CD58 expression in hematological tumors is frequently related to treatment response and longer survival, while CD58 loss contributes to immune evasion, facilitates the emergence of resistance to immunotherapies like CAR-T cell therapy, and indicates a poorer prognosis. Here, CD58 is linked to hematopoietic and lymphoid system neoplasm.